Prediction of Plasma CtDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer

No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests but its utility for risk stratification is unclear. Here, we intersect ctDNA%, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre phase II trials and a prospective province-wide blood biobanking program. ctDNA% correlates with serum and radiographic metrics of disease burden and is highest in patients with liver metastases. ctDNA% strongly predicts overall survival, progression-free survival, and treatment response independent of therapeutic context and outperformed established prognostic clinical factors. Recognizing that ctDNA-based biomarker genotyping is limited by low ctDNA% in some patients, we leverage the relationship between clinical prognostic factors and ctDNA% to develop a clinically-interpretable machine-learning tool that predicts whether a patient has sufficient ctDNA% for informative ctDNA genotyping (available online: https://www.ctDNA.org ). Our results affirm ctDNA% as an actionable tool for patient risk stratification and provide a practical framework for optimized biomarker testing.

Citing Articles

Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment Response.

Li A, Lou E, Leder K, Foo J JCO Clin Cancer Inform. 2025; 9:e2400160.

PMID: 40053881 PMC: 11895822. DOI: 10.1200/CCI-24-00160.

5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies.

Li Q, Huang C, Huang S, Tian Y, Huang J, Bitaraf A Commun Med (Lond). 2025; 5(1):61.

PMID: 40038525 PMC: 11880319. DOI: 10.1038/s43856-025-00783-0.

The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer.

Cox M, Vitello D, Chawla A J Gastrointest Cancer. 2025; 56(1):44.

PMID: 39808248 DOI: 10.1007/s12029-024-01129-0.

The role of circulating tumor DNA in melanomas of the uveal tract.

Zameer M, Jou E, Middleton M Front Immunol. 2024; 15():1509968.

PMID: 39697328 PMC: 11652350. DOI: 10.3389/fimmu.2024.1509968.

Patient-Specific Circulating Tumor DNA for Monitoring Response to Menin Inhibitor Treatment in Preclinical Models of Infant Leukemia.

Doculara L, Evans K, Gooding J, Bayat N, Lock R Cancers (Basel). 2024; 16(23).

PMID: 39682177 PMC: 11640178. DOI: 10.3390/cancers16233990.

References

Smaletz O, Scher H, Small E, Verbel D, McMillan A, Regan K . Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002; 20(19):3972-82. DOI: 10.1200/JCO.2002.11.021. View

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

Armstrong A, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M . Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2009; 16(1):203-11. DOI: 10.1158/1078-0432.CCR-09-2514. View

Armstrong A, Lin P, Higano C, Sternberg C, Sonpavde G, Tombal B . Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018; 29(11):2200-2207. PMC: 6888025. DOI: 10.1093/annonc/mdy406. View

Chi K, Kheoh T, Ryan C, Molina A, Bellmunt J, Vogelzang N . A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2015; 27(3):454-60. PMC: 4769990. DOI: 10.1093/annonc/mdv594. View

Crawford E, Higano C, Shore N, Hussain M, Petrylak D . Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015; 194(6):1537-47. DOI: 10.1016/j.juro.2015.06.106. View

Scher H, Morris M, Stadler W, Higano C, Basch E, Fizazi K . Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016; 34(12):1402-18. PMC: 4872347. DOI: 10.1200/JCO.2015.64.2702. View

Corcoran R, Chabner B . Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018; 379(18):1754-1765. DOI: 10.1056/NEJMra1706174. View

Ignatiadis M, Sledge G, Jeffrey S . Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5):297-312. DOI: 10.1038/s41571-020-00457-x. View

10.

Cescon D, Bratman S, Chan S, Siu L . Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2022; 1(3):276-290. DOI: 10.1038/s43018-020-0043-5. View

11.

Reichert Z, Morgan T, Li G, Castellanos E, Snow T, DallOlio F . Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2022; 34(1):111-120. PMC: 9805517. DOI: 10.1016/j.annonc.2022.09.163. View

12.

Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C . Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. EBioMedicine. 2020; 54:102728. PMC: 7186589. DOI: 10.1016/j.ebiom.2020.102728. View

13.

Annala M, Fu S, Bacon J, Sipola J, Iqbal N, Ferrario C . Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021; 32(7):896-905. DOI: 10.1016/j.annonc.2021.03.205. View

14.

Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C . Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. Eur Urol. 2021; 80(2):243-253. PMC: 8329366. DOI: 10.1016/j.eururo.2021.05.030. View

15.

Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg C, Jones R . Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Ann Oncol. 2021; 32(6):726-735. DOI: 10.1016/j.annonc.2021.03.196. View

16.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner E . Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov. 2018; 8(4):444-457. DOI: 10.1158/2159-8290.CD-17-0937. View

17.

Annala M, Taavitsainen S, Khalaf D, Vandekerkhove G, Beja K, Sipola J . Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clin Cancer Res. 2021; 27(16):4610-4623. DOI: 10.1158/1078-0432.CCR-21-1625. View

18.

Norgaard M, Bjerre M, Fredsoe J, Vang S, Jensen J, De Laere B . Prognostic Value of Low-Pass Whole Genome Sequencing of Circulating Tumor DNA in Metastatic Castration-Resistant Prostate Cancer. Clin Chem. 2023; 69(4):386-398. DOI: 10.1093/clinchem/hvac224. View

19.

Tukachinsky H, Madison R, Chung J, Gjoerup O, Severson E, Dennis L . Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clin Cancer Res. 2021; 27(11):3094-3105. PMC: 9295199. DOI: 10.1158/1078-0432.CCR-20-4805. View

20.

Sumiyoshi T, Chi K, Wyatt A . Clinical implications of genomic alterations in metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021; 24(2):310-322. DOI: 10.1038/s41391-020-00308-x. View